Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 111, Issue 11
June 1 2008
Issue Cover

Table of Contents

INSIDE BLOOD

NEOPLASIA
Bak to death with chemotherapy
Jonathan W. Friedberg
View Articletitled, Bak to death with chemotherapy
HEMOSTASIS
Slipping out the Weibel-Palade body
Jan Voorberg
View Articletitled, Slipping out the Weibel-Palade body
TRANSPLANTATION
Cytomegalovirus: time for a requiem?
Jayesh Mehta
View Articletitled, Cytomegalovirus: time for a requiem?
HEMOSTASIS
Unleashed platelets in aHUS
Vahid Afshar-Kharghan
View Articletitled, Unleashed platelets in aHUS
IMMUNOBIOLOGY
Critiquing Cryos
Morie Gertz
View Articletitled, Critiquing Cryos
CLINICAL OBSERVATIONS
Lenalidomide: what is the right dose in CLL?
Thomas S. Lin
View Articletitled, Lenalidomide: what is the right dose in CLL?
IMMUNOBIOLOGY
IL-21 priming enhances T-cell immunotherapy
Phillip K. Darcy
View Articletitled, IL-21 priming enhances T-cell immunotherapy

ASH 50TH ANNIVERSARY REVIEW

The vessel wall and its interactions
Denisa D. Wagner,Paul S. Frenette
View Articletitled, The vessel wall and its interactions

PLENARY PAPERS

Selective release of molecules from Weibel-Palade bodies during a lingering kiss
Victor Babich,Athinoula Meli,Laura Knipe,John E. Dempster,Paul Skehel,Matthew J. Hannah,Tom Carter
View Articletitled, Selective release of molecules from Weibel-Palade bodies during a lingering kiss
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Clinical Trials & Observations
Alessandra Ferrajoli,Bang-Ning Lee,Ellen J. Schlette,Susan M. O'Brien,Hui Gao,Sijin Wen,William G. Wierda,Zeev Estrov,Stefan Faderl,Evan N. Cohen,Changping Li,James M. Reuben,Michael J. Keating
View Articletitled, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

HEMATOPOIESIS AND STEM CELLS

Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors
Naoya Takayama,Hidekazu Nishikii,Joichi Usui,Hiroko Tsukui,Akira Sawaguchi,Takashi Hiroyama,Koji Eto,Hiromitsu Nakauchi
View Articletitled, Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors
Supplemental data

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY

Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation
Anne-lie Ståhl,Fariba Vaziri-Sani,Stefan Heinen,Ann-Charlotte Kristoffersson,Karl-Henrik Gydell,Reem Raafat,Alberto Gutierrez,Ortraud Beringer,Peter F. Zipfel,Diana Karpman
View Articletitled, Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation
Regulation of tumor necrosis factor receptor-1 and the IKK-NF-κB pathway by LDL receptor–related protein explains the antiinflammatory activity of this receptor
Alban Gaultier,Sanja Arandjelovic,Sherry Niessen,Cheryl D. Overton,MacRae F. Linton,Sergio Fazio,W. Marie Campana,Benjamin F. Cravatt, III,Steven L. Gonias
View Articletitled, Regulation of tumor necrosis factor receptor-1 and the IKK-NF-κB pathway by LDL receptor–related protein explains the antiinflammatory activity of this receptor

IMMUNOBIOLOGY

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Christian S. Hinrichs,Rosanne Spolski,Chrystal M. Paulos,Luca Gattinoni,Keith W. Kerstann,Douglas C. Palmer,Christopher A. Klebanoff,Steven A. Rosenberg,Warren J. Leonard,Nicholas P. Restifo
View Articletitled, IL-2 and IL-21 confer opposing differentiation programs to CD8<sup>+</sup> T cells for adoptive immunotherapy
Supplemental data
Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis
David Saadoun,Michelle Rosenzwajg,Dan Landau,Jean Charles Piette,David Klatzmann,Patrice Cacoub
View Articletitled, Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis
Development and dynamics of robust T-cell responses to CML under imatinib treatment
Christiane I-U. Chen,Holden T. Maecker,Peter P. Lee
View Articletitled, Development and dynamics of robust T-cell responses to CML under imatinib treatment
Supplemental data

NEOPLASIA

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Luca Paoluzzi,Mithat Gonen,Jeffrey R. Gardner,Jill Mastrella,Dajun Yang,Jon Holmlund,Mel Sorensen,Lance Leopold,Katia Manova,Guido Marcucci,Mark L. Heaney,Owen A. O'Connor
View Articletitled, Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma
Sajjan Mittal,Neil A. Marshall,Linda Duncan,Dominic J. Culligan,Robert N. Barker,Mark A. Vickers
View Articletitled, Local and systemic induction of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T-cell population by non-Hodgkin lymphoma
Supplemental data
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
Christian Langer,Michael D. Radmacher,Amy S. Ruppert,Susan P. Whitman,Peter Paschka,Krzysztof Mrózek,Claudia D. Baldus,Tamara Vukosavljevic,Chang-Gong Liu,Mary E. Ross,Bayard L. Powell,Albert de la Chapelle,Jonathan E. Kolitz,Richard A. Larson,Guido Marcucci,Clara D. Bloomfield
View Articletitled, High <em>BAALC</em> expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
Supplemental data

RED CELLS

Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A
Ashley M. Toye,Rosalind C. Williamson,Moudji Khanfar,Brigitte Bader-Meunier,Thérèse Cynober,Madeleine Thibault,Gil Tchernia,Michèle Déchaux,Jean Delaunay,Lesley J. Bruce
View Articletitled, Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A
Supplemental data
EPO receptor circuits for primary erythroblast survival
Pradeep Sathyanarayana,Arvind Dev,Jing Fang,Estelle Houde,Olga Bogacheva,Oleg Bogachev,Madhu Menon,Sarah Browne,Anamika Pradeep,Christine Emerson,Don M. Wojchowski
View Articletitled, EPO receptor circuits for primary erythroblast survival
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis
Brief Report
Melanie J. Percy,Philip A. Beer,Gavin Campbell,Ad W. Dekker,Anthony R. Green,David Oscier,M. Glenn Rainey,Richard van Wijk,Marion Wood,Terence R. J. Lappin,Mary Frances McMullin,Frank S. Lee
View Articletitled, Novel exon 12 mutations in the <em>HIF2A</em> gene associated with erythrocytosis

TRANSPLANTATION

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
Drew J. Winston,Jo-Anne H. Young,Vinod Pullarkat,Genovefa A. Papanicolaou,Ravi Vij,Estil Vance,George J. Alangaden,Roy F. Chemaly,Finn Petersen,Nelson Chao,Jared Klein,Kellie Sprague,Stephen A. Villano,Michael Boeckh
View Articletitled, Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

CORRESPONDENCE

Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?
Agatha Labrinidis,Vasilios Liapis,Le M. Thai,Gerald J. Atkins,Cristina Vincent,Shelley Hay,Natalie A. Sims,Andrew C. W. Zannettino,David M. Findlay,Andreas Evdokiou
View Articletitled, Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?
Role of TRAIL in osteoclastogenesis
Giorgio Zauli,Paola Secchiero
View Articletitled, Role of TRAIL in osteoclastogenesis
Imatinib mesylate for platelet-derived growth factor receptor-beta–positive Erdheim-Chester histiocytosis
Julien Haroche,Zahir Amoura,Frédéric Charlotte,Juan Salvatierra,Bertrand Wechsler,Carlos Graux,Nicole Brousse,Jean-Charles Piette
View Articletitled, Imatinib mesylate for platelet-derived growth factor receptor-beta–positive Erdheim-Chester histiocytosis

BLOOD WORK

Atypical lymphocytes in Hodgkin disease
View Articletitled, Atypical lymphocytes in Hodgkin disease
All Issues

Advertisement intended for health care professionals

Interleukin-1 blockade in patients with Wiskott-Aldrich Syndrome: a retrospective multinational case series
Significant pituitary siderosis is common in transfusion dependent sickle cell disease.
Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited
How I (Diagnose and) Treat Myeloid / Lymphoid Neoplasms with Tyrosine Kinase Gene Fusions
How I treat post-immunotherapy relapsed B-ALL

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals